The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.
 
Gandhi Laurent Damaj
Consulting or Advisory Role - Amgen; Blueprint Medicines; BMS; Novartis; Takeda
Speakers' Bureau - Abbvie
Travel, Accommodations, Expenses - Abbvie; Pfizer; Takeda
 
Christian Hampp
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Emmanuel Bachy
Honoraria - Amgen; Gilead Sciences; Incyte; Janssen-Cilag; Novartis; Roche; Takeda
Consulting or Advisory Role - Gilead Sciences; Incyte; Novartis; Novartis; Roche; Takeda
Research Funding - Amgen Foundation (Inst); Bristol Myers Squibb Foundation (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Incyte; Janssen-Cilag; Roche
 
Katharina Prochazka
No Relationships to Disclose
 
Jae-Cheol Jo
No Relationships to Disclose
 
Tae Min Kim
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Daiichi Sankyo/Astra Zeneca; inno.N; Janssen Oncology; Novartis; Regeneron; Samsung Bioepis; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; IMBdx; Janssen Research & Development; Takeda
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boryung (Inst); Dizal Pharma (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); Hanmi (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
 
Lucie Oberic
Honoraria - Incyte; Janssen-Cilag; Kite/Gilead; Roche
Consulting or Advisory Role - BMSi; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
William Townsend
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Roche; Takeda
 
Jessica J Jalbert
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Qiufei Ma
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Siddhesh Kamat
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Joy Wang
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Srikanth R Ambati
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Hesham Mohamed
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Odronextamab related patents
 
Aafia Chaudhry
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
 
Eileen Thorley
Employment - IQVIA
 
Gerd Rippin
Employment - IQVIA
Stock and Other Ownership Interests - IQVIA
 
James Harnett
Employment - Regeneron
Stock and Other Ownership Interests - Pfizer; Regeneron
 
Catherine Thieblemont
Honoraria - Abbvie; Bayer; Celgene; Gilead Sciences; Incyte; Janssen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Kite/Gilead; Novartis; Roche